RP, Thanks for the post. As i have been saying for several weeks now, this company is worthy of the recognition it is starting to receive. I have been following this stock for several months now and this is my recommendation as we move into 2011. This will/should start our New Year off with a bang.
I will follow up with my complete analysis over the weekend.
By the way, are you "THE RON POPEIL OF SET IT AND FORGET IT" : )
DEPO - Solid Investment with a Short Term Catalyst
I traded DEPO earlier this year after the overreaction to XNPT's CRL sent shares below $2.50. Since then, DEPO has continued to impress and now has a forward looking event in January 2011 that could significantly increase shareholder value - the PDUFA for DM-1796 - extended release, once-daily, gabapentin tablets for pain associated with post-herpetic neuralgia (PHN). The date is 1/30/2011.
While this is a solid future catalyst, DEPO has proven that it is a great longer-term investment by continuing to drive shareholder value. With a market cap of $277mm, two marketed products and a recent, profitable Q3, DEPO is catching the eye of value investors.
I am still looking into the market potential for DM-1796, but below is some of the recent news out of DEPO as well as links to their pipeline / and AcuForm delivery technology:
News 
Market Data 
Discover 
